Regulated biocircuit systems
AssigneeObsidian Therapeutics, Inc.
InventorsPeter Barrett, Michael N. Gladstone, Tariq A. Kassum, Vipin Suri, Dan Jun Li, Dexue Sun, Brian Dolinski
Life of this patent
Estimating the term…
Abstract
The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
Claims37
A biocircuit system comprising at least one effector module, said at least one effector module each comprising
- (a) a first component and a second component wherein each of said first said second component is independently selected from the group consisting of a peptide, peptide complex, peptide-protein complex, protein, fusion protein, protein complex, protein-protein complex, and
- wherein said first component is a stimulus response element (SRE) comprising
- (i) one or more regions derived from a payload, said payload having a sequence selected from the group consisting of SEQ ID NO:
- 1-102450, and 212852-213270;
- (ii) one or more regions derived from a Target of a ligand binding partner pair listed in Table 2 or Table 3;
- (iii) one or more regions derived from an antibody listed in Table 5;
- or
- (iv) an SRE listed in Table 4, and
- wherein said second component is a payload construct comprising
- (i′) a payload, said payload having a sequence selected from the group consisting of SEQ ID NO:
- 1-102450, and 212852-213270 or functional fragment thereof;
- (ii′) a Target of a ligand binding partner pair listed in Table 2, Table 3 or functional fragment thereof;
- or
- (iii′) an antibody listed in Table 5 or a functional fragment thereof;
- and wherein said effector module is responsive to at least one stimulus.
2-3. (canceled)
(canceled)
10-20. (canceled)
(canceled)
27-35. (canceled)
A polynucleotide comprising:
- (a) a first region encoding a stimulus response element (SRE) selected from the group consisting of a peptide, a peptide complex, a peptide-protein complex, a protein, a fusion protein, a protein complex, and a protein-protein complex, said SRE comprising;
- (i) one or more regions derived from a payload, said payload having a sequence selected from the group consisting of SEQ ID NO:
- 102451-204900;
- (ii) one or more regions derived from a Target of a ligand binding partner pair listed in Table 2, Table 3;
- or
- (iii) an SRE listed in Table 4, and
- (b) a second region encoding one or more payload constructs and wherein said a payload construct comprises
- (i′) a payload, said payload having a sequence selected from the group consisting of SEQ ID NO:
- 102451-204900 or functional fragment thereof, or
- (ii′) an antibody listed in Table 5 or a functional fragment thereof;
- and
- (c) optionally, a third region encoding at least one member of the group consisting of a linker, modifier, signal sequence;
- binding domain, regulatory motif, dimerization domain, and cleavage site.
44-46. (canceled)
48-52. (canceled)
A regulatable human T cell or T cell population engineered to express an effector module.
58-65. (canceled)
69-71. (canceled)
Dependencies are inferred from the claim text.